Table 1 Baseline characteristics of the 49 Crohn’s disease patients
From: CT enterography for evaluation of disease activity in patients with ileocolonic Crohn's disease
Male gender (n, %) | 30 (61.2%) |
Median age at the inclusion (years, range) | 27 (18–69) |
Median disease duration (months, range) | 5 (1–145) |
Previous intestinal resection (n, %) | 3 (6.1%) |
Disease location | |
Ileal, n (%) | 6 (12.2%) |
Ileocolonic, n (%) | 36 (73.5%) |
Colonic, n (%) | 7 (14.3%) |
Perianal involvement, n (%) | 32 (65.3%) |
Concomitant therapies | |
5-ASA (n, %) | 31 (63.3%) |
Steroids (n, %) | 27 (55.1%) |
Immunosuppressives (n, %) | 31 (63.3%) |
Anti-TNF antibodies, n (%) | 27 (55.1%) |
Median CRP (mg/l, range) | 18.2 (0.16–113) |
Harvey–Bradshaw index, median (IQR) | 5 (1–10) |
Harvey–Bradshaw index > 4, n (%) | 26 (53.1%) |
CDEIS, median (IQR) | 9.5 (0.3–25.5) |